# US 2010/0144876 A1 · Modulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144876 A1
- Document ID: US20100144876A1
- Status: Published application
- Kind: A1
- Application number: 12/707,812
- Filed: 2010-02-18
- Published: 2010-06-10
- Earliest claimed: 2004-02-20
- Assignees: University College London
- Inventors: Masahiro Okuyama; David Selwood; Cristina Visintin; David Baker; Gareth Pryce
- Web page: https://patentgrep.com/patent/US20100144876A1

## CPC

- C07C 235/42: having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 13/10: of the bladder
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 69/76: Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C 69/78: Benzoic acid esters
- C07C 233/11: with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
- C07C 233/65: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 233/66: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C 233/69: of an acyclic saturated carbon skeleton
- C07C 235/34: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 235/78: the carbon skeleton containing rings
- C07C 235/84: with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 237/32: having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
- C07C 237/38: having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 237/42: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C07C 255/41: the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
- C07C 255/44: at least one of the singly-bound nitrogen atoms being acylated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C≡—C—(CH2)2CO2H, meta-C≡—C—(CH2)2OH, meta-C≡C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C≡C—(CH2)4OH. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

## Claims

### Claim 1

A method of treating a gastrointestinal disorder, controlling spasticity, treating spasticity, treating a disorder comprising a tremor, and/or treating a disorder comprising a muscle spasm in a subject in need thereof, said method comprising administering to the subject a compound of formula I, or a pharmaceutically acceptable salt thereof,
wherein
Z is NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group;
X—Y is selected from
—C≡C—(CH2)p—Y
—C(R5)═C(R6)—(CH2)q—Y; and
—C(R5)(R6)C(R7)(R8)—(CH2)r—Y;
wherein each of R5, R6, R7, and R8 is independently H or alkyl, and each of p, q and r is independently 2, 3, or 4;
Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4,
CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group;
A is phenyl; and
B is (CH2)n where n is 0.

### Claim 2 (depends on 1)

The method of claim 1 wherein Y is selected from CN, OH, COOR3, SO2NR3R4, CONR3R4, where each of R3 and R4 is independently H or a hydrocarbyl group.

### Claim 3 (depends on 1)

The method of claim 1 wherein each of R1, R2, R3 and R4 is independently H, an alkyl group, an aryl group, or a cycloalkyl group, each of which may be optionally substituted.

### Claim 4 (depends on 1)

The method of claim 1 wherein Y is selected from OH, CN, COOR3, CONR3R4, where each of R3 and R4 is independently H or an optionally substituted alkyl group.

### Claim 5 (depends on 1)

The method of claim 1 wherein Y is selected from OH, CN, COOMe, COOH, CONH2, CONHMe and CONMe2.

### Claim 6 (depends on 1)

The method of claim 1 wherein X—Y is selected from
—C≡C—(CH2)p—Y; and
—CH═CH—(CH2)q—Y;
wherein each of p and q is independently 2, 3 or 4.

### Claim 7 (depends on 1)

The method of claim 1 wherein X—Y is
cis-C(R5)═C(R6)—(CH2)q—Y and q is 2, 3 or 4.

### Claim 8 (depends on 1)

The method of claim 1 wherein X—Y is —C(Me)2-CH2—(CH2)r—Y and r is 2, 3 or 4.

### Claim 9 (depends on 1)

The method of claim 1 wherein Z is NR1R2 and each of R1 and R2 is independently H, an alkyl or a cycloalkyl group, each of which may be optionally substituted by one or more OH or halogen groups.

### Claim 10 (depends on 1)

The method of claim 1 wherein Z is selected from NHCH2CH2F, NH-cyclopropyl, NHCH(Me)CH2OH and NHCH2CH2 OH.

### Claim 11 (depends on 1)

The method of claim 1 wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The method of claim 1 wherein the compound is

### Claim 13 (depends on 12)

The method of claim 12 wherein the compound is in the form of a racemic mixture.

### Claim 14 (depends on 1)

The method according to claim 1 wherein Y is selected from NO2, CN, OR3, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group.

### Claim 15 (depends on 1)

The method of claim 1 wherein Y is selected from CN, COOR3, SO2NR3R4, CONR3R4, where each of R3 and R4 is independently H or a hydrocarbyl group.

### Claim 16 (depends on 1)

The method of claim 1 wherein said subject is in need of treatment for a gastric ulcer, paralytic ileus, Crohn's disease, secretory diarroehea, incontinence, asthma, bronchial spasms, hic-coughs, CREAE, MS, spasticity, Parkinson's disease, Huntingdon's Chorea, spinal cord injury, epilepsy, Tourette's syndrome, bladder spasticity and/or bladder spasm.

### Claim 17 (depends on 11)

The method of claim 11 wherein said subject is in need of treatment for a gastric ulcer, paralytic ileus, Crohn's disease, secretory diarroehea, incontinence, asthma, bronchial spasms, hic-coughs, CREAE, MS, spasticity, Parkinson's disease, Huntingdon's Chorea, spinal cord injury, epilepsy, Tourette's syndrome, bladder spasticity and/or bladder spasm.

### Claim 18 (depends on 12)

The method of claim 12 wherein said subject is in need of treatment for a gastric ulcer, paralytic ileus, Crohn's disease, secretory diarroehea, incontinence, asthma, bronchial spasms, hic-coughs, CREAE, MS, spasticity, Parkinson's disease, Huntingdon's Chorea, spinal cord injury, epilepsy, Tourette's syndrome, bladder spasticity and/or bladder spasm.

### Claim 19 (depends on 13)

The method of claim 13 wherein said subject is in need of treatment for a gastric ulcer, paralytic ileus, Crohn's disease, secretory diarroehea, incontinence, asthma, bronchial spasms, hic-coughs, CREAE, MS, spasticity, Parkinson's disease, Huntingdon's Chorea, spinal cord injury, epilepsy, Tourette's syndrome, bladder spasticity and/or bladder spasm.
